Sherlock Biosciences’ 221b Foundation Enables Global Access to COVID-19 Diagnostics with Up To 10 Million Tests Per Month
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies, Cooper International, LogicInk, Rokline, United PPE and binx health, The 221b Foundation has enabled manufacturing and global distribution in the U.S., United Arab Emirates, India and Singapore, and is in discussions to expand beyond these geographies to increase access for vital diagnostic solutions around the world.
The 221b Foundation was founded to aid in the fight against the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from third-party sales of SHERLOCK CRISPR COVID-19 products have supported programs that promote racial and gender diversity in STEM, including HMS MEDscience, Scratch and The Akilah Institute.
“As the world mobilized to respond to the COVID-19 pandemic, our mission obligated us to be part of the global solution. The 221b Foundation is one of our most important responses – an open innovation model to provide our comprehensive CRISPR IP estate to expedite the end of the pandemic,” said Rahul Dhanda, co-founder, president and CEO of Sherlock Biosciences. “Since launching the Foundation, we have enabled a variety of use cases from point-of-care to strategic testing centers in the country of Nepal to highly automated clinical environments. We are honored to be meeting this global need while creating pathways for programs that support gender and racial diversity in STEM, a vital step to ensure our industry reflects the communities it serves around the world.”
Since receiving Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration in May 2020 for its Sherlock™ CRISPR SARS-CoV-2 kit – the first FDA-authorized use of CRISPR technology – The 221b Foundation has continued to increase access to the technology through partnerships around the world.
“Since launching The 221b Foundation, we have continued to advance the platform workflow to provide a high-throughput, low cost and incredibly accurate solution to patients worldwide, while advancing the field of CRISPR diagnostics with innovations building on our discovery of new Cas enzymes to enable fully integrated, real-time multiplex testing,” said William J. Blake, Ph.D., Chief Technology Officer, Sherlock Biosciences. “Our and our partners’ assays are highly effective at detecting new, highly transmissible COVID-19 variants, making them a powerful solution to this global public health crisis.”
To learn more about licensing opportunities or our CRISPR SARS-CoV-2 method, contact us directly at sales@sherlock.bio or read our White Paper here.
About The 221b Foundation
The 221b Foundation was founded with the dual mission to assist in the eradication of COVID-19, while supporting racial and gender diversity in STEM. By providing support and intellectual property that enables both non-profit and for-profit entities to develop CRISPR-based diagnostic testing, The 221b Foundation seeks to aid in the fight against the global COVID-19 pandemic while furthering access and diversity in STEM industries. Led by industry experts in the fields of diagnostic testing, STEM and diversity, The 221b Foundation envisions a world where advances in CRISPR technology fuel the innovations that will put an end to the COVID-19 pandemic. For more information, please visit: 221bfoundation.org.
About Sherlock Biosciences
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of SHERLOCK™, a CRISPR-based method for “smart amplicon detection,” and INSPECTR™, a synthetic biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests and disease detection in the field. In 2020, the company made history with the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005110/en/
Contact information
Katie Engleman, 1AB
katie@1abmedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 06:00:00 EEST | Press release
AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 23:01:00 EEST | Press release
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune system and the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inc
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 23:01:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co
TSMC Celebrates 30th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 22:30:00 EEST | Press release
TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu
Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 19:50:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom